nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.11.2014 | Neuroimaging (DJ Brooks, Section Editor)

The Relationship between Amyloid Deposition, Neurodegeneration, and Cognitive Decline in Dementia

verfasst von: Rik Vandenberghe

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Amyloid imaging has been clinically approved for measuring β amyloid plaque load in patients being evaluated for Alzheimer's disease or other causes of cognitive decline. Here we explore a multidimensional approach to cognitive decline, where we situate amyloid plaque burden among a number of other relevant dimensions, such as aging, volume loss, other proteinopathies such as TDP43 and Lewy bodies, and functional reorganisation of cognitive brain systems. The multidimensional model incorporates a 'pure AD' trajectory, corresponding to e.g. monogenic Alzheimer's disease, but leaves room for other combinations of biomarker abnormalities (e.g. volume loss without amyloid positivity) and other trajectories. More tools will become available in the future that allow one to carve out a causal-mechanistic space for explaing cognitive decline in a personalized manner, enhancing progress towards more efficacious interventions.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRef

2.••

Clark C, Pontecorvo M, Beach T, Bedell B, Coleman R, Doraiswamy P, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78. This pivotal paper establishes the validity of ¹⁸ F-florbetapir as a marker of neuritic amyloid plaque density.

Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol. 2013;41:11–8.PubMedCrossRef

Vandenberghe R, Adamczuk K, Dupont P, Van Laere K, Chételat G. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin. 2013;2:497–511.PubMedPubMedCentralCrossRef

Rinne J, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. (11)C-PIB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.PubMedCrossRef

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198–207.PubMedCrossRef

Salloway S, Sperling R, Fox NC, Blennow K, Klunk WE, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322–33.PubMedPubMedCentralCrossRef

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. ¹⁸ F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.PubMedCrossRef

Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-β assessed by florbetapir F¹⁸ PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636–44.PubMedPubMedCentralCrossRef

10.

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74:199–208.PubMedPubMedCentral

11.••

Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71:266–73. This clinicopathological paper provides critical information about the accuracy of a clincal diagnosis of clinically probable or possible AD in a prospective multicentre academic memory clinic based series collected between 2005 and 2010 (n = 919). Compared to the standard-of-truth (neuritic plaque density and neurofibrillary tangle stage), the positive predictive value of a diagnosis of clinically probable AD ranged between 62 and 84 %; specificity between 60 % to 71 %, with a sensitivity around 73 %.PubMedPubMedCentralCrossRef

12.

Vandenberghe R, Adamczuk K, Van Laere K. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. Curr Opin Neurol. 2013;26:646–55.PubMedCrossRef

13.

Edison P, Rowe CC, Rinne JO, Nq S, Ahmed I, Kemmpainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331–8.PubMedCrossRef

14.

Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep. 2014;14:472.PubMedCrossRef

15.

Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091–105.PubMedPubMedCentralCrossRef

16.

Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet. 2010;19:R4–R11.PubMedPubMedCentralCrossRef

17.

Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302–9.PubMedCrossRef

18.

Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.PubMedPubMedCentralCrossRef

19.

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.PubMedCrossRef

20.

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409–21.PubMedCrossRef

21.

Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487–92.PubMedCrossRef

22.

Jagust WJ, Zheng L, Harvey DJ, Mack WJ, Vinters HV, Weiner MW, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol. 2008;63:72–80.PubMedPubMedCentralCrossRef

23.

Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204–12.PubMedPubMedCentralCrossRef

24.

Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040–8.PubMedPubMedCentralCrossRef

25.••

Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P, et al. Neuropathologic basis of age-associated brain atrophy. JAMA Neurol. 2013;70:616–22. From the Oregon Brain and Aging study, different measures (ventricular, total brain and hippocampal) were derived from longitudinal structural MRIs obtained in 70 cognitively intact older adults. These were correlated with clinical status, APOE status and neuropathological measures (NFT, neuritic plaques, different types of vascular lesions). Strongest correlations were obtained for ventricular and total brain measures. The correlations between these structural measures and cognition remained even after controlling for the degree of neuropathology. Hippocampal volume correlated only with the degree of amyloid angiopathy.PubMedPubMedCentralCrossRef

26.

MC Donohue, H Jacqmin-Gadda, M Le Goff, RG Thomas, R Raman, AC Gamst, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. in press, 2014.

27.•

M Bilgel, Y An, A Lang, J Prince, L Ferrucci, B Jedynak, and SM Resnick. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample. Alzheimers Dement. in press, 2014. Ultimately, efficacy of any intervention must be proven in terms of clinical parameters. From almost 900 BLSA participants, some of the most commonly used neuropsychological episodic memory measures were analyzed for their sensitivity to detect decline in the preclinical AD stage. The importance of this work lies in the high familiarity worldwide of the test parameters examined and the novel insight into the relative sensitivity of encoding versus retrieval parameters

28.

Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497–510.PubMedPubMedCentralCrossRef

29.

Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TLS, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70:857–61.PubMedPubMedCentralCrossRef

30.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PIB-PET longitudinal study. Brain. 2012;135:2126–39.PubMedCrossRef

31.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67.PubMedCrossRef

32.

Jack CR, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology. 2014;82:1605–12.PubMedPubMedCentralCrossRef

33.

Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology. 2012;78:477–84.PubMedCrossRef

34.••

Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804. From the Dominantly Inherited Alzheimer Network, multimodal cross-sectional data were analyzed from 50 symptomatic and 50 asymptomatic mutation carriers and 100 noncarrier siblings. This study provides critical empirical evidence for the orderly sequence of changes in in vivo biomarkers in monogenic AD up to 30 years prior to expected disease onset.PubMedPubMedCentralCrossRef

35.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-β deposition in the Presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057–65.PubMedCrossRef

36.•

Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the Presenilin 1 E280A kindred: a case–control study. Lancet Neurol. 2012;11:1048–56. From the Columbian Alzheimer Prevention Initiative registry, 20 PS1 mutation carriers and 20 noncarrier siblings between 18 and 26 years of age underwent task-related fMRI, structural MRI and CSF. This study provides essential insight in the functional organization of cognitive brain systems prior to clinical disease expression.PubMedCrossRef

37.

Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6:226–30.CrossRef

38.

B Kaur, JJ Himali, S Seshadri, AS Beiser, R Au, AC McKee, et al. Association between neuropathology and brain volume in the Framingham Heart Study. Alzheimer Dis Assoc Disord. in press, 2014.

39.

Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol. 2012;8:189–202.PubMed

40.••

Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70:1418–24. In a consecutive series of 130 cases with annual cognitive assessments for more than 10 years, postmortem measures of TDP43 explained as much variability in the rate of the cognitive decline as neurofibrillary tangles. This is of high importance as it points to high clinical relevance of other proteinopathies apart from the classical AD hallmark lesions.PubMedCrossRef

41.

Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491–500.PubMed

42.

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.PubMedCrossRef

43.

Hyman BT, Gomez-Isla T. Alzheimer's disease is a laminar, regional, and neural system specific disease, not a global brain disease. Neurobiol Aging. 1994;15:353–4.PubMedCrossRef

44.

Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–9.PubMedCrossRef

45.

DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457–64.PubMedCrossRef

46.

Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–80.PubMedCrossRef

47.

Davis DG, Schmitt FA, Wekstein DR, Markesberry WR. Alzheimer neuropathologic alterations in aged cognitively intact subjects. J Neuropathol Exp Neurol. 1999;58:376–88.PubMedCrossRef

48.

Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372–84.PubMedCrossRef

49.

Kovacs GG, Milenkovic I, Wöhrer A, Höftberger R, Gelpi E, Haberler C, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365–84.PubMedCrossRef

50.

Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer's disease: The Nun study. JAMA. 1997;277:813–7.PubMedCrossRef

51.

Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135:3005–14.PubMedPubMedCentralCrossRef

52.

Kovacs G. Current concepts of neurodegenerative diseases. Eur Med J Neurol. 2014;1:78–86.

53.

Boyle PA, Wilson RS, Yu L, Barr AM, Honer WG, Schneider JA, et al. Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol. 2013;74:478–89.PubMed

54.

Iacono D, Resnick SM, O'Brien R, Zonderman AB, An Y, Pletnikova O, et al. Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. J Neuropathol Exp Neurol. 2014;73:295–304.PubMedPubMedCentralCrossRef

55.

Dickerson BC, Sperling RA. Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol. 2009;21:63–75.PubMedPubMedCentralCrossRef

56.

Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillón G, et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol. 2010;68:865–75.PubMedPubMedCentralCrossRef

57.

Jagust WJ, Mormino EC. Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15:520–6.PubMedPubMedCentralCrossRef

58.

Vandenbulcke M, Peeters R, Dupont P, Van Hecke P, Vandenberghe R. Word reading and posterior temporal dysfunction in amnestic mild cognitive impairment. Cereb Cortex. 2007;17:542–51.PubMedCrossRef

59.

Nelissen N, Vandenbulcke M, Fannes K, Verbruggen A, Peeters R, Dupont P, et al. Aβ amyloid deposition in the language system and how the brain responds. Brain. 2007;130:2055–69.PubMedCrossRef

60.

Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST. Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease. Neurology. 1996;46:692–700.PubMedCrossRef

61.

Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci. 2003;23:986–93.PubMed

62.

Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–52.PubMedCrossRef

63.

Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837–44.PubMedCrossRef

64.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–17.PubMedPubMedCentralCrossRef

65.

Adamczuk K, De Weer AS, Nelissen N, Chen K, Sleegers K, Bettens K, et al. Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein e ε4 carriers. Neuroimage Clin. 2013;2:512–20.PubMedPubMedCentralCrossRef

66.•

Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1–12. Based on a pooled analysis of 245 subjects who had undergone 18 F-florbetapir and APOE genotyping, reliable age-dependent estimates are obtained for linear amyloid increase and for amyloid-positivity as a function of age and APOE.PubMedCrossRef

67.

Yeo BTT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106:1125–65.PubMedCrossRef

68.

Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709–17.PubMedCrossRef

69.

Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42–52.PubMedPubMedCentralCrossRef

70.

Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216–27.PubMedPubMedCentralCrossRef

71.

Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, et al. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer's disease. Brain. 2014;137:2052–64.PubMedPubMedCentralCrossRef

72.

Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, et al. Spatial correlation between brain aerobic glycolysis and amyloid-β deposition. Proc Natl Acad Sci U S A. 2010;107:17763–7.PubMedPubMedCentralCrossRef

73.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, et al. In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol. 2013;73:751–61.PubMedPubMedCentralCrossRef

74.

G Chételat, R La Joie, N Villain, A Perrotin, V de La Sayette, F Eustache, and R Vandenberghe. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage: Clinical. 2013

75.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.PubMedCrossRef

76.

Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer's Disease Neuroimaging Initiative Investigators. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75:563–73.PubMedCrossRef

77.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122–31.PubMedPubMedCentralCrossRef

78.

Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry. 2013;73:422–8.PubMedPubMedCentralCrossRef

79.

Sperling RA, Aisen P, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–92.PubMedPubMedCentralCrossRef

80.

Vandenberghe R, Nelissen N, Salmon E, Ivanoiu A, Hasselbalch S, Andersen A, et al. Binary classification of ¹⁸ F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. Neuroimage. 2012;64C:517–25.

81.

Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765–75.PubMedPubMedCentralCrossRef

82.

Knopman DS, Jack Jr CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73:472–80.PubMedPubMedCentralCrossRef

83.

Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032–42.PubMedPubMedCentralCrossRef

84.

Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584–7.PubMedPubMedCentralCrossRef

85.

Knopman DS. CR Jack, Jr, H. J. Wiste, S. D. Weigand, P. Vemuri, V. Lowe, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576–82.PubMedPubMedCentralCrossRef

86.

Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. BDNF val66met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol Aging. 2013;34:2457–64.PubMedCrossRef

87.

Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14.PubMedPubMedCentralCrossRef

88.

Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336–48.PubMedPubMedCentralCrossRef

89.

Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181–92.PubMedPubMedCentralCrossRef

90.

Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle study of ageing. Ann Neurol. 2013;74:905–13.PubMedCrossRef

91.

Duara R, Loewenstein DA, Shen Q, Barker W, Potter E, Varon D, et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2013;9:295–301.PubMedCrossRef

92.

Jack Jr CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain β-amyloid load approaches a plateau. Neurology. 2013;80:890–6.PubMedPubMedCentralCrossRef

Titel: The Relationship between Amyloid Deposition, Neurodegeneration, and Cognitive Decline in Dementia
verfasst von: Rik Vandenberghe
Publikationsdatum: 01.11.2014
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 11/2014
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-014-0498-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Strategies for Streamlining Emergency Stroke Care

Paroxysmal Sympathetic Hyperactivity after Severe Brain Injury

Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies

Interdisciplinary Teamwork for the Treatment of People with Parkinson’s Disease and Their Families

Cerebral Thrombosis and Myeloproliferative Neoplasms